An overview of key potential therapeutic strategies for combat in the COVID-19 battle.
An overview of key potential therapeutic strategies for combat in the COVID-19 battle.
复制标题
作者：
新型冠状病毒（SARS-CoV-2）的突然爆发，在毒力、严重性和伤亡方面已经超过了以前的冠状病毒，如SARS CoV和MERS CoV。这种变异的流感病毒起源于中国武汉的震中，并伴随着大流行效应，以可怕的速度席卷了整个世界。在这种令人困惑的情况下，医学和科学界正在努力开发潜在的疫苗介导的根除这种病毒的方法。虽然机会真的很高，但迄今为止还没有这样的灵丹妙药的报道。为成功地将任何疫苗或潜在疗法转化为临床药物而进行的繁重的人体试验程序所需的时间也是一个主要关切。为了建立对这种大规模流行病的一些抵抗力，已经完成了对一些早期抗病毒药物的重新利用，沿着一些免疫应答替代途径的翻新，如单克隆抗体介导的中和，干扰素治疗和血浆治疗。从病毒刺突蛋白的RBD结构域开发的新药和靶向病毒蛋白酶的药物也正在进行进一步的研究，并从初步结果中显示出潜力。这篇综述文章的唯一目的是对治疗进展和方法的最新状态及其在COVID-19管理中的当前实施状态进行简要的集体概述。不同方法抑制SARS-CoV-2感染的示意图。
The sudden ravaging outbreak of a novel coronavirus, or SARS-CoV-2, in terms of virulence, severity, and casualties has already overtaken previous versions of coronaviruses, like SARS CoV and MERS CoV. Originating from its epicenter in Wuhan, China, this mutated version of the influenza virus with its associated pandemic effects has engulfed the whole world with awful speed. In the midst of this bewildering situation, medical and scientific communities are on their toes to produce the potential vaccine-mediated eradication of this virus. Though the chances are really high, to date no such panacea has been reported. The time requirements for the onerous procedures of human trials for the successful clinical translation of any vaccine or potential therapeutics are also a major concern. In order to build some resistance against this massive pandemic, the repurposing of some earlier antiviral drugs has been done, along with the refurbishment of some immune-responsive alternative avenues, like monoclonal antibody mediated neutralization, interferon treatment, and plasma therapy. New drugs developed from the RBD domain of the virus spike protein and drugs targeting viral proteases are also undergoing further research and have shown potential from preliminary results. The sole purpose of this review article is to provide a brief collective overview of the recent status of therapeutics advances and approaches, and their current state of implementation for the management of COVID-19. A schematic representation of different methods to inhibit SARS-CoV-2 infection.
登录
查看更多内容
影响因子：
7.6
作者：
Báez-Santos YM;St John SE;Mesecar AD
通讯作者：
Mesecar AD
DOI：
10.1016/j.ymthe.2017.03.035
发表时间：
2017-06-07
期刊：
Molecular therapy : the journal of the American Society of Gene Therapy
影响因子：
--
作者：
Bahl K;Senn JJ;Yuzhakov O;Bulychev A;Brito LA;Hassett KJ;Laska ME;Smith M;Almarsson Ö;Thompson J;Ribeiro AM;Watson M;Zaks T;Ciaramella G
通讯作者：
Ciaramella G
DOI：
10.1016/j.ijid.2013.12.003
发表时间：
2014-03
期刊：
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
影响因子：
--
作者：
Al-Tawfiq JA;Momattin H;Dib J;Memish ZA
通讯作者：
Memish ZA
影响因子：
6.4
作者：
Agostini ML;Andres EL;Sims AC;Graham RL;Sheahan TP;Lu X;Smith EC;Case JB;Feng JY;Jordan R;Ray AS;Cihlar T;Siegel D;Mackman RL;Clarke MO;Baric RS;Denison MR
通讯作者：
Denison MR
影响因子：
5.4
作者：
Adedeji, Adeyemi O.;Severson, William;Sarafianos, Stefan G.
通讯作者：
Sarafianos, Stefan G.